The protective role of antibody responses during Mycobacterium tuberculosis infection

Clinical and Experimental Immunology

Volumn 157, Issue 2, 2009, Pages 235-243

  Abebe, F ^a   Bjune, G ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Antibody; Antigen; Immunity; Schistosomiasis; Tuberculosis

Indexed keywords

BCG VACCINE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; DRUG DESIGN; HUMAN; IMMUNOMODULATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; SCID MOUSE; TH1 CELL; TH2 CELL; TUBERCULOSIS;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; MICE; MICE, SCID; MODELS, ANIMAL; MODELS, IMMUNOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; TH1 CELLS; TH2 CELLS; TUBERCULOSIS VACCINES;

EID: 67650671886     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03967.x     Document Type: Review

References (52)

1. World Health Organization (WHO). Global tuberculosis control; surveillance, planning financing. WHO/HTM/TB/2008.393. Geneva, Switzerland: WHO, 2008.
2. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995 346 : 1339 45.
3. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. 1998 11 : 514 32.
4. Doherty TM, Andersen P. Vaccines for tuberculosis: novel concepts and recent progress. Clin Microbiol 2005 18 : 687 702. (Pubitemid 41504511)
5. Mosmann TR, Cofmann RL. TH1 and TH2 cells. Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989 7 : 145 73.
6. Gor DO, Rose NR, Greenspan NS. TH1-TH2: a procrustean paradigm. Nat Immunol 2003 4 : 503 5.
7. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med 2003 8 : 223 46.
8. Chaouat G. The Th1/Th2 paradigm: still important in pregnancy Semin Immunopathol 2007 29 : 95 113. (Pubitemid 47603024)
9. Spellberg B, Edwards JE Jr. Typ1/Typ2 immunity in infectious diseases. Clin Infect Dis 2001 32 : 76 102.
10. O'Garra A, Viera P. T(H) cells control themselves by producing interleukin-10. Nat Rev Immunol 2007 7 : 425 8.
11. Bettelli E, Ouka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007 8 : 345 50.
12. Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol Rev 2008 226 : 106 71.
13. Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 2003 3 : 23 34.
14. Hoehlig K, Lampropoulou V, Roch T et al. Immune regulation by B cells and antibodies: a view towards the clinic. Adv Immunol 2008 98 : 1 38.
15. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 2003 47 : 833 6.
16. Moore AC, Hutchings C. Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity. Exp Rev Vaccines 2007 6 : 111 21.
17. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008 21 : 225 42.
18. Bergquist NR, Colley DG. Schistosomiasis vaccines: research to development. Parasitol Today 1998 14 : 99 104. (Pubitemid 28101506)
19. Correa-Oliveira R, Caldas IR, Gazzinelli G. Natural versus drug-induced resistance in Schistosoma mansoni infection. Parasitol Today 2000 16 : 397 9.
20. Voldermeier HM, Venkataprasad N, Harris DP, Ivanyi J. Increase in tuberculous infection in organs of B cell-deficient mice. Clin Exp Immunol 1996 106 : 312 16.
21. Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol 2007 178 : 7222 34.
22. Guirado E, Amat I, Gil O et al. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect 2006 8 : 1252 59.
23. Lopez Y, Yero D, Falero-Diaz G et al. Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16 kDa protein in a modell of progresive pulmonary infection. Int J Med Microbiol 2009 15 : 1229 37.
24. Pethe K, Alonso S, Biet F et al. The heparin-binding hemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001 412 : 190 4.
25. Chambers MA, Gavier-Widen D, Hewinson RG. Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge. FEMS Immunol Med Microbiol 2004 41 : 93 100. (Pubitemid 38625710)
26. Roy E, Stavropoulos E, Brennan J et al. Therapeutic efficacy of high does intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 2005 73 : 6101 09.
27. Williams A, Relijic R, Naylor I et al. Passive protection with immunoglobulin A antibodies against tuberculosis early infection of the lungs. Immunology 2004 111 : 328 33.
28. Teitelbaum R, Glatman-Freedman A, Chen B et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA 1998 95 : 15688 93.
29. Hamasur B, Haile M, Pawlowski A et al. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol 2004 138 : 30 8.
30. Hamasur B, Haile M, Pawlowski A et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 2003 21 : 4081 93.
31. Glatman-Freedman A, Casadevall A, Dai Z et al. Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannan. J Clin Microbiol 2004 42 : 3225 31.
32. Palma C, Iona E, Gionnoni F et al. LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN response. Vaccine 2008 26 : 4237 43.
33. Kohama H, Umemura M, Okamoto Y et al. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesion suppresses extrapulmonary dissemination of Mycobacterium bovis bacilli Calmette-Guerin (BCG) in infected mice. Vaccine 2008 26 : 924 32.
34. Chang-Hong S, Xiao-wu W, Hai Z et al. Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT fusion protein from Mycobacterium tuberculosis. DNA Cell Biol 2008 27 : 199 207.
35. Teixeira FM, Teixeira HC, Ferreira AP et al. DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice. Clin Vaccine Immunol 2006 13 : 930 5.
36. Giri PK, Verma I, Khuller GK. Enhanced immunoprotective potential of Mycobacterium Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intransal adminstration. FEMS Immunol Med Microbiol 2006 47 : 233 41.
37. Xue T, Stavropoulos E, Yang M et al. RNA encoding the MTP83 antigen induces protective immune responses against Mycobacterium tuberculosis infection. Infect Immun 2004 72 : 6324 9.
38. Grover A, Ahmed MF, Singh B et al. A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microb Infect 2006 8 : 2390 9.
39. Parra M, Pickett T, Delogu G et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 2004 72 : 6799 805.
40. Sanchez-Rodriguez C, Estrada-Chavez C, Garcia-Vigil J et al. An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totanaca Indians with pulmonary tuberculosis. Int J Tuberc Lung Dis 2002 6 : 706 12.
41. Abebe F, Holm-Hansen C, Wiker HG, Bjune G. Progress in serodiagnosis of Mycobacterium tuberculosis infection. Scand J Immunol 2007 66 : 176 91.
42. de Valliere S, Abate G Blazevic A et al. Enhancement of cell-mediated immunity by antimycobacterial antibodies. Infect Immun 2005 73 : 6711 20.
43. Relijic R, Ivanyi J. A case for passive immunoprophylaxis against tuberculosis. Lancet Infect Dis 2006 6 : 813 18.
44. Brown RM, Cruz O, Brennan M et al. Lipoarabinomannan-reactive human secretory immunoglobulin response induced by mucosal bacilli Calmette-Guerin vaccination. J Infect Dis 2003 187 : 513 7.
45. Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 2008 5 : 399 407. (Pubitemid 351773101)
46. Kaplan G, Ghandi RR, Weinstein DE et al. Mycobacterium lepare antigen-induced suppression of T cell proliferation in vitro. J Immunol 1987 138 : 3582 8.
47. Moreno C, Mehiert A, Lamb J. The inhibitory effects of mycobacterial lipoarabinomannan and polysaccharides upon polyclonal and monoclonal human T cell proliferation. Clin Exp Immunol 1988 74 : 206 10.
48. Chan J, Fan X, Hunter SW et al. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun 1991 59 : 1755 61.
49. Sibley LD, Adams LB, Krahenbuhl JL. Inhibition of interferon gamma-mediated activation in mouse macrophages treated with lipoarabinomannan. Clin Exp Immunol 1990 80 : 141 8.
50. Casadevall A, Pirofski A. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 2006 91 : 1 44. (Pubitemid 44286993)
51. Casadevall A. Antibody-mediated protection against intracellular pathogens. Trends Micobiol 1998 6 : 102 7.
52. Boyton RJ, Openshaw PJ. Pulmonary defence to acute respiratory infections. Br Med Bull 2002 61 : 1 12. (Pubitemid 34477552)